Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 Study

Journal of Immunotherapy and Precision Oncology · Published 2025-01-14 · DOI 10.36401/jipo-24-8

Authors being retrieved — see the publisher record. https://doi.org/10.36401/jipo-24-8

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year: 2025

Related articles

Characterizing Inquiries About Novel Cancer Therapies: Findings from the National Cancer Institute’s Cancer Information Service · Journal of Immunotherapy and Precision Oncology · 2025 · Same journal
More Than Medicine: The Hope, Hurdles, and Hidden Costs of IgG Therapy · Journal of Immunotherapy and Precision Oncology · 2025 · Same journal
Advancing Understanding and Therapeutic Strategies for NUT Sarcomas: Comprehensive Review of the Literature and Two Cases · Journal of Immunotherapy and Precision Oncology · 2025 · Same journal
Bispecific Antibodies in Solid Tumors: Mechanistic Insights, Clinical Advances, and Future Directions · Journal of Immunotherapy and Precision Oncology · 2026 · Same journal
Management of Hepatitis B Virus and Hepatitis C Virus Infections in Patients with Cancer Receiving Immune Checkpoint Inhibitors · Journal of Immunotherapy and Precision Oncology · 2024 · Same journal
Impact of Germline BRCA Status on Pathologic Complete Response (pCR) and Outcomes in Early TNBC Treated with Pembrolizumab-Based Neoadjuvant Chemotherapy (KEYNOTE-522 Regimen): A Real-World Study · Journal of Immunotherapy and Precision Oncology · 2026 · Same journal
Learning From Mistakes: Navigating Medical Errors in Oncology From Prevention to Management · Journal of Immunotherapy and Precision Oncology · 2024 · Same journal
SMARCA4-Directed Treatment in Oncology Clinical Trials: A Review · Journal of Immunotherapy and Precision Oncology · 2026 · Same journal
Impact of COVID-19 on Management and Outcomes of Oncology Patients: Results of MENA COVID-19 and Cancer Registry (MCCR) · Journal of Immunotherapy and Precision Oncology · 2024 · Same journal
Beyond Visibility: Social Media, Trust, and Responsibility in Oncology · Journal of Immunotherapy and Precision Oncology · 2026 · Same journal